LEXINGTON, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,735,557, entitled “Activated Sialic Acid Derivatives for Protein Derivatization and Conjugation,” with claims that cover lead compound, ErepoXen®, and Xenetic’s broader polysialic acid technologies.
Help employers find you! Check out all the jobs and post your resume.
